Dr. Divers is originally from Mississippi. He received a bachelor’s degree from Centenary College of Louisiana and his medical degree from Louisiana State University School of Medicine. He completed his residency at the University of North Carolina and received the David A. Ontjes Outstanding Intern Award, was named the Outstanding Second Year Resident, received the Chairman’s Award, and was named Senior Resident of the Year. He completed his fellowship at the University of Alabama at Birmingham Cancer Center, which has been named in the top 20 cancer centers in the nation by U.S. News & World Report. Dr. Divers is board certified in internal medicine, medical oncology, and hematology.
Russell Ingersoll joined Trapelo Health as Chief Product Officer in 2010 bringing 20+ years of healthcare information technology experience and proven track-record of commercializing information technology products for the clinical and life science industries. His team is responsible for building and implementing Trapelo Health programs with oncologists, laboratories, and health insurance organizations. Prior to joining Trapelo, Russ served as VP of Product Development for MedTrust Online, an oncology-centric information portal; Senior Director of Business Development at Phylogeny, Inc., a functional genomics services company; co-founder of Folio Biosciences, a biobank of clinically annotated cancer specimens and co-founder of BioProtocol, an interactive laboratory protocol system for the research community.
Russ received a BS in Molecular and Cellular Biology from the University of Arizona, a Ph.D. in Pharmacology and Toxicology from the University of Arizona College of Pharmacy and completed his post-doctoral training at the University of California, Berkeley.
Vice President, Personalized Medicine, Sarah Cannon; Scientific Director, Genospace
Dr. McKenzie joined Sarah Cannon in 2015 and serves as the vice president of Sarah Cannon’s Personalized Medicine Program. He also serves as the scientific director for Genospace, Sarah Cannon’s precision medicine platform.
McKenzie has more than 10 years of basic science and translational research experience in oncology. In his role, Dr. McKenzie is responsible for providing scientific and operational oversight for implementing Sarah Cannon’s personalized medicine strategy. He and the personalized medicine program provide scientific, consultative and programmatic services to clinical research investigators, study sponsors, research personnel and other healthcare providers to advance Sarah Cannon’s molecular profiling efforts. As scientific director at Genospace, McKenzie is responsible for providing scientific and strategic guidance to data science and product development activities.
Prior to joining Sarah Cannon, Dr. McKenzie was a research fellow in the cancer biology department at Vanderbilt University’s Vanderbilt-Ingram Cancer Center where he investigated extracellular vesicle trafficking and translational cell biology research. He earned a Bachelor of Science from Shorter College and a Doctor of Philosophy in pharmacology from The University of Vermont where he investigated extracellular matrix remodeling and cell motility.
Chief Executive Officer, Carolina Blood and Cancer Care Associates; President, Community Oncology Alliance
Kashyap Patel, MD, is the CEO of Carolina Blood and Cancer Care Associates in Rock Hill, South Carolina, and president of the Community Oncology Alliance (COA).
A full-time practicing medical oncologist, board-certified in hematology, oncology, and internal medicine, Dr. Patel also volunteers with many other leading national cancer and quality organizations. He is a consultant Medical Director for the Blue Cross Blue Shield of South Carolina (BCBSS); a CAC member for DHHS (SC) and Palmetto GBA; Medical Director of the International Oncology Network. Dr. Patel is past president of the South Carolina Oncology Society and has served as chairman of several committees in numerous South Carolina hospitals. He has testified before the South Carolina State Senate and briefed countless members of the United States Congress and their staff on critical community oncology issues.
With extensive expertise in value-based care, Dr. Patel has successfully led multiple oncology payment pilots in his practice and consulted on others across the state and nation. He has published or presented more than 70 original articles and abstracts in journals and/or meetings (nationally and internationally). Through this work, Dr. Patel received research merit awards for cancer research, including ASCO merit awards during his fellowship.
Dr. Patel has a special interest in health care policy, with a focus on racial and ethnic disparities and end of life care. An accomplished author, he recently published “Between Life and Death: From Despair to Hope,” a firsthand chronicle of real patients who have faced the end of life with understanding and acceptance. Dr. Patel is also associate editor in chief of Evidence-Based Oncology, a publication of the American Journal of Managed Care.
Dr. Patel also has extensive experience in revenue cycle management (RCM) in oncology, including co-founding a large RCM company that has grown from four employees to more than 1,000 employees today. He recently started a research enterprise, the Community Clinical Oncology Research Network (CCORN), to support the recruitment and increased participation of independent oncology practices in cancer clinical research.
Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives, Texas Oncology
Dr. Patt is the executive vice president for policy, payer relations, and strategic initiatives. In this role she helps advocate for effective cancer policy at the state and federal level, and advises on strategy for various initiatives, such as telemedicine, optimizing growth and development of advanced practice providers, development of service lines, informatics initiatives and contracting.
Dr. Patt is a practicing oncologist and breast cancer specialist in Austin, Texas, and an active leader in breast cancer research, serving on the US Oncology Research breast cancer committee. She is a leader in clinical cancer informatics and is involved in system innovations to enhance care delivery. She is the editor-in-chief of the Journal of Clinical Oncology- Clinical Cancer Informatics. Dr. Patt is on the executive committee and the board of directors for the Community Oncology Alliance, the Council on Legislation for the Texas Medical Association, the nominating committee for the American Society of Clinical Oncology, and is president-elect for the Texas Society of Clinical Oncology.
Medical Director, Clinical Research Program, Florida Cancer Specialists
Dr. James Reeves joined Florida Cancer Specialists in 1988, only four years after the group was founded; he has
consistently been a driving force in the growth of the practice, especially as it relates to clinical trial research. Published
frequently in such prestigious journals as Blood, Journal of Clinical Oncology, New England Journal of Medicine and
Clinical Genitourary Cancer, Dr. Reeves has extensive research experience, having served as either Principal Investigator or Sub Investigator on over 130 Phase I, II and III Clinical Trials for a broad spectrum of cancers, including, but not limited to, multiple myeloma, renal cell carcinoma, chronic lymphocytic leukemia, metastatic breast cancer, prostate cancer, colorectal cancer, lung cancer, gastroesophageal cancer and pancreatic cancer. Dr. Reeves’ unwavering dedication to clinical trial research has helped to significantly increase the body of knowledge about cancer treatment and helped to develop many promising new drugs and therapies for our patients.
Chief Medical Officer, Tennessee Oncology, a partner of OneOncology
Stephen completed medical school at Vanderbilt and residency at Brigham and Women’s Hospital. While there he was selected into Harvard’s McArthur Healthcare Leadership Fellowship which included a fully funded MBA from Harvard Business School. During that time Stephen worked as a consultant at McKinsey and Company and performed research in palliative care. Stephen then left Boston to complete oncology training at Memorial Sloan Kettering before coming back to his home town of Nashville to join Tennessee Oncology where he is now Chief Medical Officer. Prior this role, Stephen was Medical Director of Value-Based Care for OneOncology, a community oncology network spanning over 700 oncology providers practicing across 300 clinics throughout the country. Stephen also serves as President of the Tennessee Oncology Practice Society and is the current Co-Chair of the American Cancer Society’s Nashville Real Men Wear Pink campaign to raise money for breast cancer research and awareness.